Lv12
32 积分 2024-06-30 加入
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era
4小时前
已关闭
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
4小时前
已完结
QUADAS-3: A Revised Tool for the Quality Assessment of Diagnostic Test Accuracy Studies
3天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
13天前
已完结
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
1个月前
已完结
Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
1个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
1个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
1个月前
已完结
Conversion Surgery for Initially Unresectable Stage Ⅲ Nonsmall Cell Lung Cancer After Induction Treatment of Immunochemotherapy: A Multicenter Study
1个月前
已完结
What’s the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer: a real-world study
1个月前
已完结
皖公网安备34019202002308
